Dataset Information

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.

ABSTRACT: We have previously reported a series of anilinoquinazoline derivatives as potent and selective biochemical inhibitors of the RET kinase domain. However, these derivatives displayed diminished cellular potency. Herein we describe further optimisation of the series through modification of their physicochemical properties, delivering improvements in cell potency. However, whilst cellular selectivity against key targets could be maintained, combining cell potency and acceptable pharmacokinetics proved challenging.

SUBMITTER: Jordan AM

PROVIDER: S-EPMC4896930 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.

Jordan Allan M AM Begum Habiba H Fairweather Emma E Fritzl Samantha S Goldberg Kristin K Hopkins Gemma V GV Hamilton Niall M NM Lyons Amanda J AJ March H Nikki HN Newton Rebecca R Small Helen F HF Vishwanath Swamy S Waddell Ian D ID Waszkowycz Bohdan B Watson Amanda J AJ Ogilvie Donald J DJ

Bioorganic & medicinal chemistry letters 20160330 11

We have previously reported a series of anilinoquinazoline derivatives as potent and selective biochemical inhibitors of the RET kinase domain. However, these derivatives displayed diminished cellular potency. Herein we describe further optimisation of the series through modification of their physicochemical properties, delivering improvements in cell potency. However, whilst cellular selectivity against key targets could be maintained, combining cell potency and acceptable pharmacokinetics prov ...[more]

PMID: 27086121

Dataset Information

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.

Publications

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Similar Datasets

RET kinase inhibitors for <i>RET</i>-altered thyroid cancers.
| S-EPMC9218446 | biostudies-literature

Discovery of Bivalent Kinase Inhibitors via Enzyme-Templated Fragment Elaboration.
| S-EPMC4538437 | biostudies-literature

Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
| S-EPMC3731256 | biostudies-literature

Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET<sup>V804M</sup> Kinase.
| S-EPMC7153033 | biostudies-literature

Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism.
| S-EPMC3089571 | biostudies-literature

Drug resistance profiles of mutations in the RET kinase domain.
| S-EPMC6086982 | biostudies-literature

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.
| S-EPMC4457528 | biostudies-literature

Design, Synthesis and Inhibitory Activity of Photoswitchable RET Kinase Inhibitors.
| S-EPMC4421829 | biostudies-other

Mechanistic insight into RET kinase inhibitors targeting the DFG-out conformation in RET-rearranged cancer
2017-06-21 | PXD006006 | Pride

Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.
| S-EPMC5682201 | biostudies-literature